Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has signed a written informed consent to participate in the study and has agreed to follow dosing instructions and complete all required study visits.~* The patient is a pregnant female age equal to or greater than 18 years old.~* The patient's entry ultrasound indicates a viable pregnancy and confirms gestational age of the fetus is 7-14 weeks at the anticipated time of the first dose of study medication or placebo. If an ultrasound was done within 4 weeks of the admission visit, and results can be obtained, an additional ultrasound is not necessary.~* The patient is suffering from NVP and has a Pregnancy Unique Quantification of Emesis (PUQE) score ≥6.~* The patient has not responded to conservative management consisting of dietary/lifestyle advice according to the 2004 ACOG Practice Bulletin.~* The patient agrees, if on a multivitamin, to continue on their current dose of multivitamin for the duration of the trial.~* The patient does not plan termination of the pregnancy.~Exclusion Criteria:~* The investigator confirms the patient's nausea and vomiting is of etiology other than Nausea and Vomiting of Pregnancy (NVP).~* The patient has gestational trophoblastic disease or multifetal gestation.~* The patient has a condition for which antihistamines, in the opinion of the investigator, are contraindicated (epilepsy, alcoholism, glaucoma, chronic lung disease, urinary retention, heart block, etc.).~* The patient has used antihistamines, anticholinergics, dopamine antagonists, serotonin antagonists, ginger, or anti-emetic therapy (including acupressure, acupuncture, homeopathic remedies, medical hypnosis, relief bands etc) to treat NVP in the previous 48 hours or plans to do so during the study .~* The patient is using drugs that have anticholinergic activity (e.g., tricyclic antidepressants).~* The patient is taking multivitamins containing more than 10 mg of vitamin B6, or plans to do so during the study.~* The patient is taking supplementary vitamin B6 in addition to any multivitamin preparation, or plans to do so during the study.~* The patient is currently drinking any amount of alcohol.~* The patient has any condition that might interfere with the conduct of the study.~* The patient is likely to be unable to comply with study procedures because of inadequate cognitive skills.~* The patient has received an investigational drug within 30 days before enrollment in this study or is scheduled to receive an investigational drug during the course of this study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diclectin® (Type: EXPERIMENTAL): Diclectin® (doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg) delayed release tablet
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets identical in size, shape, taste, and color to the experimental treatment (Diclectin®)

Based on this trial design, predict the completion outcome and termination type (if applicable).